These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 32677086)

  • 1. The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases.
    Calzaferri F; Ruiz-Ruiz C; de Diego AMG; de Pascual R; Méndez-López I; Cano-Abad MF; Maneu V; de Los Ríos C; Gandía L; García AG
    Med Res Rev; 2020 Nov; 40(6):2427-2465. PubMed ID: 32677086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P2X7 receptor: an emerging target in central nervous system diseases.
    Sperlágh B; Illes P
    Trends Pharmacol Sci; 2014 Oct; 35(10):537-47. PubMed ID: 25223574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P2X7 Receptors Amplify CNS Damage in Neurodegenerative Diseases.
    Illes P
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Activity Relationships and Therapeutic Potential of Purinergic P2X7 Receptor Antagonists.
    El Idrissi IG; Podlewska S; Abate C; Bojarski AJ; Lacivita E; Leopoldo M
    Curr Med Chem; 2024; 31(11):1361-1403. PubMed ID: 37013427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P2X7 receptors: channels, pores and more.
    Volonté C; Apolloni S; Skaper SD; Burnstock G
    CNS Neurol Disord Drug Targets; 2012 Sep; 11(6):705-21. PubMed ID: 22963440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting calciumopathy for neuroprotection: focus on calcium channels Cav1, Orai1 and P2X7.
    Torres-Rico M; García-Calvo V; Gironda-Martínez A; Pascual-Guerra J; García AG; Maneu V
    Cell Calcium; 2024 Nov; 123():102928. PubMed ID: 39003871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2X7 Receptor Antagonist A804598 Inhibits Inflammation in Brain and Liver in C57BL/6J Mice Exposed to Chronic Ethanol and High Fat Diet.
    Freire D; Reyes RE; Baghram A; Davies DL; Asatryan L
    J Neuroimmune Pharmacol; 2019 Jun; 14(2):263-277. PubMed ID: 30353422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P2X7 Receptor: an Emerging Target in Alzheimer's Disease.
    Huang Q; Ying J; Yu W; Dong Y; Xiong H; Zhang Y; Liu J; Wang X; Hua F
    Mol Neurobiol; 2024 May; 61(5):2866-2880. PubMed ID: 37940779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A current review on P2X7 receptor antagonist patents in the treatment of neuroinflammatory disorders: a patent review on antagonists.
    Soni S; Lukhey MS; Thawkar BS; Chintamaneni M; Kaur G; Joshi H; Ramniwas S; Tuli HS
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4643-4656. PubMed ID: 38349395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P2X7 receptor antagonists: a patent review (2010-2015).
    Park JH; Kim YC
    Expert Opin Ther Pat; 2017 Mar; 27(3):257-267. PubMed ID: 27724045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P2X7 Purinergic Receptor Is Involved in the Pathophysiology of Mania: a Preclinical Study.
    Gubert C; Andrejew R; Leite CE; Moritz CEJ; Scholl J; Figueiro F; Kapczinski F; da Silva Magalhães PV; Battastini AMO
    Mol Neurobiol; 2020 Mar; 57(3):1347-1360. PubMed ID: 31729632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats.
    Antonioli L; Giron MC; Colucci R; Pellegrini C; Sacco D; Caputi V; Orso G; Tuccori M; Scarpignato C; Blandizzi C; Fornai M
    PLoS One; 2014; 9(12):e116253. PubMed ID: 25549098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P2X7 purinergic receptor: A potential target in heart diseases (Review).
    Bin Dayel AF; Alonazi AS; Alshammari TK; Alrasheed NM
    Mol Med Rep; 2023 Mar; 27(3):. PubMed ID: 36799169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in the Development of Antidepressants Targeting the Purinergic P2X7 Receptor.
    Lee S; Ha H; Jang J; Byun Y
    Curr Med Chem; 2023; 30(2):164-177. PubMed ID: 35770396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018-present).
    Iqbal J; Bano S; Khan IA; Huang Q
    Expert Opin Ther Pat; 2024 Apr; 34(4):263-271. PubMed ID: 38828613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional P2X
    Prades S; Heard G; Gale JE; Engel T; Kopp R; Nicke A; Smith KE; Jagger DJ
    J Neurosci; 2021 Mar; 41(12):2615-2629. PubMed ID: 33563723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P2X7 receptor antagonism prevents IL-1β release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy.
    Khalafalla MG; Woods LT; Camden JM; Khan AA; Limesand KH; Petris MJ; Erb L; Weisman GA
    J Biol Chem; 2017 Oct; 292(40):16626-16637. PubMed ID: 28798231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of P2X7 Receptor Ameliorates Nuclear Factor-Kappa B Mediated Neuroinflammation Induced by Status Epilepticus in Rat Hippocampus.
    Huang C; Chi XS; Li R; Hu X; Xu HX; Li JM; Zhou D
    J Mol Neurosci; 2017 Oct; 63(2):173-184. PubMed ID: 28856625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purinergic P2X7 receptor as a potential therapeutic target in depression.
    Qi W; Jin X; Guan W
    Biochem Pharmacol; 2024 Jan; 219():115959. PubMed ID: 38052270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purinergic P2X
    Mckenzie ADJ; Garrett TR; Werry EL; Kassiou M
    ACS Chem Neurosci; 2022 May; 13(10):1479-1490. PubMed ID: 35512313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.